about
Dendrimer advances for the central nervous system delivery of therapeuticsAnti-HIV-1 nanotherapeutics: promises and challenges for the futureMagnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers.Nanotechnology and MRI contrast enhancementCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyIn vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsionsPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Methods for isolation and identification of nanoparticle-containing subcellular compartments.Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsLong-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.HIV-1 neuroimmunity in the era of antiretroviral therapy.Pathogenesis of HIV in the central nervous systemEmerging nanotechnology approaches for HIV/AIDS treatment and prevention.Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrierDesigning Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.Registered bioimaging of nanomaterials for diagnostic and therapeutic monitoring.Cell-mediated drug delivery.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesSustained-release nanoART formulation for the treatment of neuroAIDSCompartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update.Nanotechnology and the treatment of HIV infection.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityPreclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyNanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.Update on HIV-associated neurocognitive disorders.HIV-1 Latency and Eradication: Past, Present and FutureNeurodegenerative disorders and nanoformulated drug development.Investigational protease inhibitors as antiretroviral therapies.A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemNeuroimmune pharmacology of neurodegenerative and mental diseases.HIV-associated neurological disorders: a guide to pharmacotherapy.Advances in brain targeting and drug delivery of anti-HIV therapeutic agents.Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.
P2860
Q26828423-C674214C-9B00-497F-821C-609FC6699280Q26828464-8176692C-4A74-4A35-90C2-C7A28E66CC4BQ27317660-3B6A86CB-63CC-4248-9A46-F5FDBF2D3656Q28307795-107CE342-8DB1-4147-8F72-5B9CD92923F7Q28551873-81D64BB2-4D4D-43C2-9F16-2D4F581605D1Q30469832-B6EFDE7F-DD50-4A85-8085-517DEE24A68FQ30603781-6D1A9751-C1AB-42AF-BFAC-1F231D0E448FQ33561837-DF557BD8-3DC7-4DD6-9955-391A1CD85862Q33614467-AA6BCFE4-D88C-4652-88CA-F1EC9E988FF4Q33625213-27670958-FBA7-45A9-8DDF-8944717D8402Q33733529-AAEB3564-FE94-4FB6-8DCF-11C7B7DCA5E9Q33781978-099227E1-B933-4A7B-8618-198A6F1A8A26Q33819656-C5CFE1AD-F2F7-47AE-87D9-5BF5988E3DBEQ33831400-9795B0CC-D077-456D-B1A7-9ED0AB39F998Q34504098-445AFB3D-301D-426D-B9F3-DB94F68EDDC2Q34639915-0A7B4F3A-FDA3-40DB-8C5B-178317E49A5CQ34709440-345B8D11-B795-4822-9F45-5634D7E799B6Q34728884-237E9EB1-B077-4235-8327-719366263CCFQ34797004-9780A9A9-5339-4E06-90BA-5691A3D04158Q35082009-D3D0BFDE-6F7E-4FAB-8CB2-4DAC19A03251Q35606068-88A26C9B-A4EC-4C7C-A02B-64E08D1ACD36Q35677168-7CB925C1-873D-4E1A-9D10-AE20312C99F5Q35708840-00C47847-33A6-4AC6-A468-70F33184D4E5Q35943647-34A5F9E7-AF96-425B-9412-6AC81A0FA62CQ35979166-8F19A980-EDD1-470F-83C7-1FF0F2885371Q36107193-D191D295-D46A-49A3-99A0-9A641AB9C81BQ36603756-0102320F-618B-4847-BF02-B3B328444B96Q36875347-DBE32DB5-8CF5-4BA4-B6DA-8DC36B237736Q36969787-35E26D00-8DC6-4722-9D6C-392A96DB44C8Q37013364-0D03109D-733A-4C50-94B5-9D630E4868B4Q37200962-79F63BAF-48B1-4AD3-AF03-18DBBC648DEBQ37505823-142FC14C-D9C1-4FA1-A392-C924C8DF3329Q37538771-7CC3F827-28FC-4927-8143-32E541C2E977Q37582521-CEFFC10B-545E-4CBA-87E8-9E70BF78541CQ37617639-7AEEE9F0-4F12-4771-BC8B-923C33CAD5CBQ37698620-33B6F5CA-A0AE-4D6E-8886-64A2A0B84562Q37785813-F78AE51C-C8E9-408A-88C1-90FA30356C37Q37971469-000FCD62-07B0-4382-9650-E6518F90F461Q38091126-770C1BC6-85DF-4B21-B595-63597DFAC0C8Q38130176-B10E7D9E-631E-4EAE-87B6-A2C65EED9E9B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NanoART, neuroAIDS and CNS drug delivery.
@en
NanoART, neuroAIDS and CNS drug delivery.
@nl
type
label
NanoART, neuroAIDS and CNS drug delivery.
@en
NanoART, neuroAIDS and CNS drug delivery.
@nl
prefLabel
NanoART, neuroAIDS and CNS drug delivery.
@en
NanoART, neuroAIDS and CNS drug delivery.
@nl
P2860
P356
P1433
P1476
NanoART, neuroAIDS and CNS drug delivery.
@en
P2093
Ari Nowacek
Howard E Gendelman
P2860
P304
P356
10.2217/NNM.09.38
P577
2009-07-01T00:00:00Z